Breaking News on Contract Research, Manufacturing & Clinical Trials

Top Headlines

House introduces companion bill to offer CROs a share of R&D tax credit

In a House bill that largely mirrors one reintroduced earlier this year in the Senate, CROs (contract research organizations) would be able to capture a share of the R&D tax credit, thereby making the US more competitive with other countries that offer such credits.

CROs look to buttress research models businesses with CRISPR/Cas tech

As the largest pharma and tech suppliers – from Novartis to GE Healthcare to Thermo Fisher – begin exploring the world of CRISPR/Cas gene editing technology, contract research organizations are also looking into the new tech to explore ways to help clients’ research models.

EMA re-confirms drug suspensions due to faulty trial data from GVK Biosciences

Following a re-examination requested by MAHs (marketing authorisation holders) for seven of the medicines suspended, the EMA has re-confirmed its recommendation to suspend hundreds of drugs following issues with clinical studies conducted at CRO GVK Biosciences in Hyderabad, India. 

WuXi adding ADC tech to services in Ambrx acquisition

A consortium including WuXi PharmaTech has agreed to acquire biotech client Ambrx for its antibody-drug conjugate (ADC) conjugation technology.

inVentiv expands NIS services to help stem confusion on new EU trials regulation

inVentiv Health has expanded its compliance products and services to assist biopharma companies conducting non-interventional studies (NIS). 

News in brief

Amarantus selects Chiltern for Phase IIb study

Neurologically-focused biotech Amarantus BioScience has entered into a clinical trial agreement with CRO Chiltern to manage the clinical research and monitoring program services for the Phase IIb study of eltoprazine in Parkinson’s disease levodopa-induced dyskinesia (PD-LID).

Key Industry Events


Access all events listing

Our events, Shows & Conferences...